# Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

> **NCT00957372** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 253 (actual)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** eslicarbazepine acetate
- **DRUG:** placebo (Part I)
- **DRUG:** ESL - Open-label Extension (Part II)

## Key facts

- **NCT ID:** NCT00957372
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2014-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00957372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00957372, "Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00957372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*